Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring.

Kawaguchi Y, Hajika Y, Rinka M, Masumoto K, Sawa J, Hamazaki K, Kumeda Y

Journal of diabetes investigation23 Jan 2024Cited by 7 (Europe PMC)

PMID38258482PMCIDPMC11060164DOI10.1111/jdi.14151PepBankPUB-38258482

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, time in range and time below range level 1 did not differ significantly between insulin degludec/liraglutide and insulin glargine U100/lixisenatide.
In plain wordsIn adults with type 2 diabetes, time in range and time with low glucose were similar with the two insulin-plus-GLP-1 combinations.
Peptide
Liraglutide
Outcome
No significant changeTime in range and time below range level 1
Study
n = 36
Comparator
Insulin glargine U100/lixisenatide
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The TIR and TBR level 1 showed no significant differences between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Insulin glargine U100/lixisenatide and insulin degludec/liraglutide are fixed-ratio combinations containing basal insulin and a glucagon-like peptide-1 receptor agonist capable of reducing both fasting and postprandial blood glucose levels with a single formulation.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3825848201
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, changes in glycemic variability were not significantly different between insulin degludec/liraglutide and insulin glargine U100/lixisenatide.
In plain wordsIn adults with type 2 diabetes, changes in glucose variability were similar with the two combinations.
Peptide
Liraglutide
Outcome
No significant changeGlycemic variability
Study
n = 36
Comparator
Insulin glargine U100/lixisenatide
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The changes in glycemic variability, therapeutic indices, and body mass index were not significantly different among the groups (P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Insulin glargine U100/lixisenatide and insulin degludec/liraglutide are fixed-ratio combinations containing basal insulin and a glucagon-like peptide-1 receptor agonist capable of reducing both fasting and postprandial blood glucose levels with a single formulation.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3825848202
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, changes in therapeutic indices were not significantly different between insulin degludec/liraglutide and insulin glargine U100/lixisenatide.
In plain wordsIn adults with type 2 diabetes, changes in treatment indices were similar with the two combinations.
Peptide
Liraglutide
Outcome
No significant changeTherapeutic indices
Study
n = 36
Comparator
Insulin glargine U100/lixisenatide
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The changes in glycemic variability, therapeutic indices, and body mass index were not significantly different among the groups (P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Insulin glargine U100/lixisenatide and insulin degludec/liraglutide are fixed-ratio combinations containing basal insulin and a glucagon-like peptide-1 receptor agonist capable of reducing both fasting and postprandial blood glucose levels with a single formulation.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3825848203
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, changes in body mass index were not significantly different between insulin degludec/liraglutide and insulin glargine U100/lixisenatide.
In plain wordsIn adults with type 2 diabetes, changes in BMI were similar with the two combinations.
Peptide
Liraglutide
Outcome
No significant changeBody mass index
Study
n = 36
Comparator
Insulin glargine U100/lixisenatide
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The changes in glycemic variability, therapeutic indices, and body mass index were not significantly different among the groups (P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Insulin glargine U100/lixisenatide and insulin degludec/liraglutide are fixed-ratio combinations containing basal insulin and a glucagon-like peptide-1 receptor agonist capable of reducing both fasting and postprandial blood glucose levels with a single formulation.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3825848204
05HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with type 2 diabetes, the baseline C-peptide index correlated positively with time in range at 18 weeks in both fixed-ratio combination groups (r = 0.679 and r = 0.681).
In plain wordsIn adults with type 2 diabetes, a higher baseline C-peptide index went with more time in range on both combinations.
Peptide
Liraglutide
Outcome
Not applicableCorrelation between baseline C-peptide index and time in range at 18 weeks
Study
n = 36
Outcome group
Glycemic control · Metabolic and weight
Measurements
r
0.679
first group
r
0.681
second group
Source sentences
Summary
Both groups showed significant positive correlations between the C-peptide index and the TIR (P = 0.002, r = 0.679; P = 0.002, r = 0.681, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Insulin glargine U100/lixisenatide and insulin degludec/liraglutide are fixed-ratio combinations containing basal insulin and a glucagon-like peptide-1 receptor agonist capable of reducing both fasting and postprandial blood glucose levels with a single formulation.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3825848205
06HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with type 2 diabetes on insulin degludec/liraglutide, the baseline C-peptide index cut-off to achieve time in range above 70% at 18 weeks was 1.099 (sensitivity 57.1%, specificity 90.9%).
In plain wordsIn adults with type 2 diabetes on insulin degludec/liraglutide, a baseline C-peptide index of 1.099 marked who reached over 70% time in range.
Peptide
Liraglutide
Outcome
Not applicableC-peptide index cut-off for time in range above 70%, insulin degludec/liraglutide
Study
n = 36
Outcome group
Glycemic control · Metabolic and weight
Measurements
C-peptide index cut-off
1.099
insulin degludec/liraglutide
Sensitivity
57.1%
insulin degludec/liraglutide
Specificity
90.9%
insulin degludec/liraglutide
Source sentences
Summary
1.099 (sensitivity, 57.1%; specificity, 90.9%) in the insulin glargine U100/lixisenatide and insulin degludec/liraglutide groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Insulin glargine U100/lixisenatide and insulin degludec/liraglutide are fixed-ratio combinations containing basal insulin and a glucagon-like peptide-1 receptor agonist capable of reducing both fasting and postprandial blood glucose levels with a single formulation.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3825848206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.